Technical Analysis for ALNA - Allena Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
5.16 | 2.99% | 0.15 |
ALNA closed down 4.39 percent on Friday, October 18, 2019, on 2.0 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| See historical ALNA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Upper Bollinger Band Walk | Strength | 2.99% | |
| Inside Day | Range Contraction | 2.99% | |
| Wide Bands | Range Expansion | 2.99% | |
| Overbought Stochastic | Strength | 2.99% | |
| Upper Bollinger Band Touch | Strength | 2.99% | |
| New Uptrend | Bullish | -1.53% | |
| Pocket Pivot | Bullish Swing Setup | -1.53% | |
| Volume Surge | Other | -1.53% | |
| Upper Bollinger Band Walk | Strength | -1.53% | |
| Wide Bands | Range Expansion | -1.53% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
- Sector: Healthcare
- Industry: Biotechnology
Allena Pharmaceuticals, Inc. is a United States-based specialty biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones. ALLN-177 is an orally administered, recombinant oxalate-degrading enzyme. ALLN-177 targets oxalate in the gastrointestinal (GI) tract to reduce the burden of both dietary and endogenously produced oxalate. ALLN-177 has the potential to decrease the oxalate available systemically for deposition as calcium oxalate crystals or stones in the kidneys, as well as to reduce the incidence of calcium oxalate related complications. Its technological approach enables the design and development of oral protein therapies that remain in the GI tract.
Medicine Biopharmaceutical Medical Specialties Organ Systems Kidney Diseases Anticoagulants Hyperoxaluria
Medicine Biopharmaceutical Medical Specialties Organ Systems Kidney Diseases Anticoagulants Hyperoxaluria
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more ALNA news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 10.66 |
| 52 Week Low | 3.33 |
| Average Volume | 82,011 |
| 200-Day Moving Average | 5.5441 |
| 50-Day Moving Average | 4.1946 |
| 20-Day Moving Average | 4.27 |
| 10-Day Moving Average | 4.581 |
| Average True Range | 0.3796 |
| ADX | 27.27 |
| +DI | 32.6997 |
| -DI | 9.7676 |
| Chandelier Exit (Long, 3 ATRs ) | 4.2512 |
| Chandelier Exit (Short, 3 ATRs ) | 4.4688 |
| Upper Bollinger Band | 5.1205 |
| Lower Bollinger Band | 3.4195 |
| Percent B (%b) | 0.94 |
| BandWidth | 39.836066 |
| MACD Line | 0.1924 |
| MACD Signal Line | 0.0796 |
| MACD Histogram | 0.1128 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.58 | ||||
| Resistance 3 (R3) | 5.60 | 5.42 | 5.49 | ||
| Resistance 2 (R2) | 5.42 | 5.28 | 5.42 | 5.45 | |
| Resistance 1 (R1) | 5.22 | 5.19 | 5.13 | 5.20 | 5.42 |
| Pivot Point | 5.04 | 5.04 | 5.00 | 5.04 | 5.04 |
| Support 1 (S1) | 4.84 | 4.90 | 4.75 | 4.82 | 4.60 |
| Support 2 (S2) | 4.66 | 4.81 | 4.66 | 4.57 | |
| Support 3 (S3) | 4.46 | 4.66 | 4.54 | ||
| Support 4 (S4) | 4.44 |
